Status:

COMPLETED

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborating Sponsors:

Brigham and Women's Hospital

Massachusetts General Hospital

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (...

Detailed Description

* Not every patient will be receiving the same dose of capecitabine and navelbine. A small group will be enrolled onto the study and given certain doses of each drug. If they tolerate them well (have ...

Eligibility Criteria

Inclusion

  • Histologically confirmed breast cancer with evidence of locally advanced or metastatic disease
  • Female patients age 18 or older
  • No more than three prior chemotherapeutic regimens in the metastatic setting
  • ANC \> 1,500/mm3
  • Platelet count \> 100,000/mm3
  • SGOT \< 3 x ULN
  • Bilirubin \< 1.5 x ULN
  • Performance status of 0 or 1
  • At least 3 weeks since prior chemotherapy or 2 weeks since prior radiation, surgery or any anticancer investigational agent
  • Able to swallow and retain oral medications
  • Measurable disease

Exclusion

  • Prior vinca alkaloids
  • Active gastrointestinal disease or disorder
  • Pregnant or lactating
  • Serious co-morbid medical or psychological condition
  • Prior bone marrow or stem cell transplant
  • Prior documented severe sensitivity to 5-FU

Key Trial Info

Start Date :

March 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2011

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00153907

Start Date

March 1 2002

End Date

September 1 2011

Last Update

February 7 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115